- Home
- ETON vs HFRO Comparison
ETON vs HFRO Comparison
Compare ETON & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- HFRO
- Stock Information
- Founded
- ETON 2017
- HFRO 2000
- Country
- ETON United States
- HFRO United States
- Employees
- ETON N/A
- HFRO N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- HFRO Finance/Investors Services
- Sector
- ETON Health Care
- HFRO Finance
- Exchange
- ETON Nasdaq
- HFRO Nasdaq
- Market Cap
- ETON 388.3M
- HFRO 340.3M
- IPO Year
- ETON 2018
- HFRO N/A
- Fundamental
- Price
- ETON $17.68
- HFRO $6.59
- Analyst Decision
- ETON Strong Buy
- HFRO
- Analyst Count
- ETON 3
- HFRO 0
- Target Price
- ETON $29.67
- HFRO N/A
- AVG Volume (30 Days)
- ETON 206.2K
- HFRO 179.8K
- Earning Date
- ETON 11-11-2025
- HFRO 01-01-0001
- Dividend Yield
- ETON N/A
- HFRO 8.87%
- EPS Growth
- ETON N/A
- HFRO N/A
- EPS
- ETON N/A
- HFRO N/A
- Revenue
- ETON $58,181,000.00
- HFRO N/A
- Revenue This Year
- ETON $105.25
- HFRO N/A
- Revenue Next Year
- ETON $40.84
- HFRO N/A
- P/E Ratio
- ETON N/A
- HFRO N/A
- Revenue Growth
- ETON 85.40
- HFRO N/A
- 52 Week Low
- ETON $5.35
- HFRO $4.24
- 52 Week High
- ETON $21.48
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- ETON 59.16
- HFRO 86.03
- Support Level
- ETON $17.24
- HFRO $6.10
- Resistance Level
- ETON $18.52
- HFRO $6.23
- Average True Range (ATR)
- ETON 0.66
- HFRO 0.08
- MACD
- ETON -0.07
- HFRO 0.02
- Stochastic Oscillator
- ETON 54.10
- HFRO 97.40
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.